Siopel Publications

2014

Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy.

Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL.

Curr Opin Pediatr. 2014 Feb;26(1):19-28.

Abstract

PURPOSE OF REVIEW:

As a rare pediatric tumor, hepatoblastoma presents challenges to the individual practitioner as no center will see more than a handful of cases each year.

RECENT FINDINGS:

The Children's Hepatic tumor International Collaborative (CHIC) effort has fostered international cooperation in this rare children's tumor, leading to the establishment of a large international collaborative dataset, the CHIC database, which has been interrogated to refine risk stratification and inform treatment options. Apace with this effort has been the international collaboration of pediatric pathologists working together to establish a new international histopathologic consensus classification for pediatric liver tumors as a whole, with particular focus on the histological subtypes of hepatoblastoma.

SUMMARY:

International collaborative efforts in hepatoblastoma have led to a new international histopathologic consensus classification, refinements in risk stratification, advances in chemotherapy, and a better understanding of surgical resection options forming the foundation for the development of an upcoming international therapeutic trial.

2013

 

Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium.

López-Terrada DAlaggio Rde Dávila MTCzauderna PHiyama EKatzenstein HLeuschner IMalogolowkin MMeyers RRanganathan STanaka Y,Tomlinson GFabrè MZimmermann AFinegold MJ.

Modern Pathology 2013 Sep 6.

Abstract

Liver tumors are rare in children, and their diagnoses may be challenging particularly because of the lack of a current consensus classification system. Systematic central histopathological review of these tumors performed as part of the pediatric collaborative therapeutic protocols has allowed the identification of histologic subtypes with distinct clinical associations. As a result, histopathology has been incorporated within the Children's Oncology Group (COG) protocols, and only in the United States, as a risk-stratification parameter and for patient management. Therefore, the COG Liver Tumor Committee sponsored an International Pathology Symposium in March 2011 to discuss the histopathology and classification of pediatric liver tumors, and hepatoblastoma in particular, and work towards an International Pediatric Liver Tumors Consensus Classification that would be required for international collaborative projects. Twenty-two pathologists and experts in pediatric liver tumors, including those serving as central reviewers for the COG, European Société Internationale d'Oncologie Pédiatrique, Gesellschaft für Pädiatrische Onkologie und Hämatologie, and Japanese Study Group for Pediatric Liver Tumors protocols, as well as pediatric oncologists and surgeons specialized in this field, reviewed more than 50 pediatric liver tumor cases and discussed classic and newly reported entities, as well as criteria for their classification. This symposium represented the first collaborative step to develop a classification that may lead to a common treatment-stratification system incorporating tumor histopathology. A standardized, clinically meaningful classification will also be necessary to allow the integration of new biological parameters and to move towards clinical algorithms based on patient characteristics and tumor genetics, which should improve future patient management and outcome.

 

Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.

Zsiros JBrugieres LBrock PRoebuck DMaibach RZimmermann AChilds MPariente DLaithier VOtte JBBranchereau SAronson D,Rangaswami ARonghe MCasanova MSullivan MMorland BCzauderna PPerilongo GInternational Childhood Liver Tumours Strategy Group (SIOPEL).

Lancet Oncology 2013 Aug;14(9):834-42.

Abstract

BACKGROUND:

The objective of this study was to establish the efficacy and safety of a new treatment regimen consisting of dose-dense cisplatin-based chemotherapy and radical surgery in children with high-risk hepatoblastoma.

METHODS:

SIOPEL-4 was a prospective single-arm feasibility study. Patients aged 18 years or younger with newly diagnosed hepatoblastoma with either metastatic disease, tumour in all liver segments, abdominal extrahepatic disease, major vascular invasion, low α fetoprotein, or tumour rupture were eligible. Treatment consisted of preoperative chemotherapy (cycles A1-A3: cisplatin 80 mg/m(2) per day intravenous in 24 h on day 1; cisplatin 70 mg/m(2) per day intravenous in 24 h on days 8, 15, 29, 36, 43, 57, and 64; and doxorubicin 30 mg/m(2) per day intravenous in 24 h on days 8, 9, 36, 37, 57, and 58) followed by surgical removal of all remaining tumour lesions if feasible (including liver transplantation and metastasectomy, if needed). Patients whose tumour remained unresectable received additional preoperative chemotherapy (cycle B: doxorubicin 25 mg/m(2) per day in 24 h on days 1-3 and 22-24, and carboplatin area under the curve [AUC] 10·6 mg/mL per min per day intravenous in 1 h on days 1 and 22) before surgery was attempted. After surgery, postoperative chemotherapy was given (cycle C: doxorubicin 20 mg/m(2) per day in 24 h on days 1, 2, 22, 23, 43, and 44, and carboplatin AUC 6·6 mg/mL per min per day in 1 h on days 1, 22, and 43) to patients who did not receive cycle B. The primary endpoint was the proportion of patients with complete remission at the end of treatment. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00077389.

FINDINGS:

We report the final analysis of the trial. 62 eligible patients (39 with lung metastases) were included and analysed. 60 (98%, 95% CI 91-100) of 61 evaluable patients (one child underwent primary hepatectomy) had a partial response to preoperative chemotherapy. Complete resection of all tumour lesions was achieved in 46 patients (74%). At the end of therapy, 49 (79%, 95% CI 67-88) of 62 patients were in complete remission. With a median follow-up of 52 months, 3-year event-free survival was 76% (95% CI 65-87) and 3-year overall survival was 83% (73-93). 60 (97%) patients had grade 3-4 haematological toxicity (anaemia, neutropenia, or thrombocytopenia) and 44 (71%) had at least one episode of febrile neutropenia. Other main grade 3 or 4 toxicities were documented infections (17 patients, 27%), anorexia (22, 35%), and mucositis (seven, 11%). One child died of fungal infection in neutropenia. Moderate-to-severe ototoxicity was documented in 31 (50%) patients. 18 serious adverse events (including two deaths) reflecting the observed side-effects were reported in the trial (the most common was ototoxicity in five patients).

INTERPRETATION:

The SIOPEL-4 treatment regimen is feasible and efficacious for complete remission at the end of treatment for patients with high-risk hepatoblastoma.

 

Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.

Weeda VBMurawski MMcCabe AJMaibach RBrugières LRoebuck DFabre MZimmermann AOtte JBSullivan MPerilongo GChilds MBrock P,Zsíros JPlaschkes JCzauderna PAronson DC.

 

Eur J Cancer 2013 Aug;49(12):2698-704.

Abstract

PURPOSE:

Fibrolamellar hepatocellular carcinoma (FL-HCC) and conventional hepatocellular carcinoma (HCC) cases in two consecutive paediatric HCC trials were analysed to compare outcome and derive treatment implications.

PATIENTS AND METHODS:

Data of 24 FL-HCC (24% PRETEXT IV) and 38 HCC (42% PRETEXT IV) cases from SIOPEL-2 and -3 (1995-1998, 1998-2006) were analysed. Patients were treated according to SIOPEL-2 and -3 high-risk protocol (carboplatin+doxorubicin alternating with cisplatin; seven preoperative, three postoperative cycles) or with primary surgery followed by chemotherapy as indicated.

RESULTS:

Thirteen of 24 FL-HCC (54%) and 32/38 HCC (84%) were initially treated with chemotherapy. Eight FL-HCC (33%) and five HCC patients (13%) had primary surgery. Partial response was observed in 31% of FL-HCC versus 53% of HCC patients (p=0.17). Complete resection was achieved in ten FL-HCC and seven HCC patients (p=0.08). Three-year event free survival (EFS) was 22% for FL-HCC versus 28% for HCC. Overall survival (OS) was not significantly different at 3 years follow up (42% for FL-HCC versus 33% for HCC, p=0.24). EFS/OS Kaplan-Meier curves did not differ significantly, with median follow up of 43 (FL-HCC) and 60 (HCC) months. No significant correlation was found between potential prognostic factors and OS. In the entire cohort nine out of 23 (39%) patients with complete resection or orthotopic liver transplantation versus 34/39 (87%) without successful surgical treatment, died.

CONCLUSIONS:

Long-term OS in FL-HCC and HCC is similar. With low response rates, complete resection remains the treatment of choice.

 

2010

Successful treatment of childhood high risk hepatoblastoma with dose intensive multiagent chemotherapy and surgery - final results of the SIOPEL-3HR study of the  international childhood liver tumor strategy group

József Zsíros, Rudolf Maibach, Elizabeth Shafford, Laurence Brugieres,  Penelope Brock, Piotr Czauderna, Derek Roebuck, Margaret Childs, Arthur Zimmermann, Jack Plaschkes, Jean-Bernard Otte, Beatriz de Camargo, Gordon MacKinlay, Marcelo Scopinaro, Daniel Aronson15, Giorgio Perilongo

 

J Clin Oncol. 2010 May 20;28(15):2584-90.

2009

Cisplatin alone versus Cisplatin/Doxorubicin for standard risk hepatoblastoma; final report of the randomized international trial, SIOPEL 3 SR-HB 
Giorgio Perilongo  MD (1), Rudolf Maibach (2) PhD, Elisabeth Shafford MD (3), Laurence Brugieres MD (4), Penelope Brock MD (5), Bruce Morland MD (6), Beatriz De Camargo MD (7), Jozsef Zsiros MD (8), Derek Roebuck MD (5), Arthur Zimmermann MD (9), Daniel Aronson MD (10), Margaret Childs MD (3), Eva Widing (11), Veronique Laithier (4), MD, Jack Plaschkes MD (12), Jon Pritchard MD (13) *, Marcello Scopinaro MD (14), Gordon MacKinlay MD (13), Piotr Czauderna MD (15).

 

N Engl J Med 2009; 361:1662-1670

2008

Hepatic Stem-like Phenotype and Interplay of Wnt/b-Catenin and Myc Signaling in  Aggressive Childhood Liver Cancer

Stefano Cairo, Carolina Armengol, Aurelien De Reynie`s, Yu Wei, Emilie Thomas, Claire-Angelique Renard, Andrei Goga, Asha Balakrishnan, Michaela Semeraro, Lionel Gresh, Marco Pontoglio, Helene Strick-Marchand, Florence Levillayer, Yann Nouet, David Rickman, Frederic Gauthier, Sophie Branchereau, Laurence Brugieres, Vronique Laithier, Raymonde Bouvier, Francoise Boman, Giuseppe Basso, Jean-Francois Michiels, Paul Hofman, Francine Arbez-Gindre, Helene Jouan, Marie-Christine Rousselet-Chapeau, Dominique Berrebi, Luc Marcellin, Francois Plenat, Dominique Zachar, Madeleine Joubert, Janick Selves, Dominique Pasquier, Paulette Bioulac-Sage, Michael Grotzer, Margaret Childs, Monique Fabre, Marie-Annick Buendia

Cancer Cell 14, 471–484, December 9, 2008

Cisplatin Alone Versus Cisplatin/Doxorubici (PLADO) For Standard Risk Hepatoblastoma;

Final Report of the Randomised Controlled, Multi-Modality, International Collaborative  SIOPEL 3 Trial.

Giorgio Perilongo, Rudolf Maibach, Laurence Brugieres, Penelope Brock, Piotr Czauderna, Bruce Morland, Beatriz de Camargo, Jozsef Zsiros, Derek Roebuck, Arthur Zimmermann, Daniel Aronson, Margaret Childs, Elizabeth Shafford, Jack Plaschkes.

Ped Blood Cancer: SIOP 2008, Berlin, Germany.

Hepatoblsatoma with Microscopic Residual Tumor After Surgery: Results from SIOPEL 2  & 3 Trials

Daniel Aronson, Laurence Brugieres, Rudolf Maibach, Margaret Childs, Jean-Bernard Otte, Frederic Gautier, Jean de Ville de Goyet, Gordon MacKinlay, Jack Plaschkes, Giorgio Perilongo, Piotr Czauderna.

 

Ped Blood Cancer: SIOP 2008, Berlin, Germany.

2007

2005 PRETEXT: a revised staging system for primary liver tumors of childhood. Paed Radiology

Derek J Roebuck, Daniel Aronson, Philippe Clapuyt, Piotr Czauderna, Jean de Ville de Goyet, Frédéric Gauthier, Gordon MacKinlay, Kieran McHugh, Øystein Olsen, Jean-Bernard Otte, Danièle Pariente, Margaret Childs, Giorgio Perilongo, Jack Plaschkes (2006).

Paedtric Radiology 2007 February; 37(2):123-132.

Successful Treatment of High Risk Hepatomastoma – Final Results of the SIOPEL Trial   of the International Childhood Liver Tumours Strategy Group (SIOPEL).

Jozsef Zsiros, R Maibach, L Brugieres, E Shafford, P Brock, P Czauderna, D Aronson, G MacKinlay, J Otte, J Plaschkes, M Childs, G Perilongo

Ped Blood Cancer:49, Issue 4, October 1 2007.

Hepatoblastoma in Patients aged 10-18 years. Report from the the International     Childhood Liver Tumours Strategy Group (SIOPEL).

 Michela Casanova, Arthur Zimmermann, Rudolf Maibach, Margaret Childs, Penelope Brock,  Laurence Brugieres, Giorgio Perilongo, Daniel Aronson, Derek Roebuck, Jozsef Zsiros,   Patrizia Dall’Inga, Piotr Czauderan, JackPlaschkes.

Ped Blood Cancer:49, Issue 4, October 1 2007.    

Clinical Features and Outcome of Patients with Beckwith-Wiedemann Syndrome and Hepatoblastoma treated on SIOPEL 2 & 3 Clinical Trials.

Michael Sullivan, Margaret Childs, Michael Capra.

 

Ped Blood Cancer:49, Issue 4, October 1 2007.

2006

Hepatocellular carcinoma in children: where we are and where we go – first experience from the SIOPEL 3 study.
Piotr Czauderna*, Rudolf Maibach, Bruce Morland, Derek Roebuck, Arthur Zimmermann, Michela Casanova, Margaret Childs, Giorgio Perilongo.
* On behalf of the International Childhood Liver Tumors Group SIOPEL from the Dept. of Surgery and Urology for Children and Adolescents, Medical University of Gdansk, Poland. 

SIOP Pediatric Blood & Cancer Vol 47: October 2006

Cisplatin Ototoxicity in patients with Hepatoblastoma: Can it be reduced? Results from the SIOPEL Strategy Group.
P. Brock, P.Ballabeni, L.Brugieres, M.Childs, R.Maibach, G.Osterlundh, G.Perilongo J.Zsiros and J.Pritchard.

 

SIOP Pediatric Blood & Cancer Vol 47: October 2006

2005

Predictive Value of the Pretreatment Extent of Disease System in Hepatoblastoma: Results From the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 Study
Danie¨l C. Aronson, J. Marco Schnater, Chris R. Staalman, Gerrit J. Weverling, Jack Plaschkes,
Giorgio Perilongo, Julia Brown, Angela Phillips, Jean-Bernard Otte, Piotr Czauderna,
Gordon MacKinlay, and Anton Vos
J Clin Oncol. 2005 Feb 20;23(6):1245-52.

Initial low alphafoetoprotein Level Predicts a Bad Prognosis in High Risk Hepatoblastoma – Treatment results of two consecutive trials: SIOPEL 2 and SIOPEL 3.

Zsiros J, Maibach R, Brock P, Brugieres L, Pritchard J, Shafford E, Plaschkes J, Czauderna P, Aronson D, MacKinlay G, Otte J, Childs M, Ballabeni P and Perilongo G.

SIOP Paediatric Blood & Cancer Vol45:Issue4:October 2005

Metastatic Hepatoblastoma: Preliminary results of two consecutive trials SIOPEL 2 & 3 from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology.

Brock P, Maibach R, Zsiros J, Brugieres L, Pritchard J, Shafford E, Plaschkes J, Otte J, Czauderna P, Aronson D, MacKinlay G, Childs M, Ballabeni P, Perilongo G.

SIOP Paediatric Blood & Cancer Vol45:Issue4:October 2005

Guidelines for surgical treatment of hepatoblastoma in the modern era – Recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL)

Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, Plaschkes J, Perilongo G; Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL).

 

Eur J Cancer. 2005 May;41(7):1031-6.

2004

Liver transplantation (LTx) for unresectable hepatoblastoma (HB). Experience from the first co-operative study of the International Society of Pediatric Oncology - SIOPEL I - Proposal of guidelines. 
J.B. Otte 1, P. Czauderna 2, D.C. Aronson 3, G. Perilongo 4, J. Pritchard 5, E. Shafford 6, J. Brown 7, J. Plaschkes 8.
Pediatr Blood Cancer. 2004;42:74–83.

Risk adapted treatment for Childhood Hepatoblastoma; final report of the second study of the International Society of Paediatric Oncology – SIOPEL 2

G Perilongo, E Shafford, R Maibach, D Aronson, L Brugieres, P Brock, M Childs, P Czauderna, G MacKinaly, JB Otte, J Pritchard, R Rondelli, M Scopinaro, C Staalman, J Plaschkes.

Eur J Cancer 2004 40: 411-421

Hepatocellular Carcinoma in Children: Results of the First Prospective Study of the International Society of Pediatric Oncology Group
P. Czauderna, G. Mackinlay, G. Perilongo, J. Brown, E. Shafford, D. Aronson, J. Pritchard, P. Chapchap, J. Keeling, J. Plaschkes, and J.B. Otte for the Liver Tumors Study Group of the International Society of Pediatric Oncology
J Clin Oncol 2002 20:2798-2804.

Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.
Schnater JM, Aronson DC, Plaschkes J, Perilongo G, Brown J, Otte JB, Brugieres L, Czauderna P, MacKinlay G, Vos A.
Cancer 2002 Feb 15;94(4):1111-20

Proceedings of the Third SIOPEL Liver Tumour Study Group Workshop 
Zimmermann A, Plaschkes J, Perilongo G
Med Pediatr Oncol 2002 Nov; 39 ( 5 ), 473.

Proceedings of an international research workshop on pediatric liver tumours, 18-20 March 1999, Berne, Switzerland. Into the year 2000 .
Plaschkes J,  
Med Pediatr Oncol 2001 Mar;36(3):380-2

Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2.

Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, Childs M, Czauderna P, MacKinlay G, Otte JB, Pritchard J, Rondelli R, Scopinaro M, Staalman C, Plaschkes

Eur J Cancer. 2004 Feb;40(3):411-21

Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience.

Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, Perilongo G, Shafford E, Plaschkes J; International Society of Pediatric Oncology (SIOP).

Pediatr Blood Cancer. 2004 Jan;42(1):74-83

Update of the SIOPEL 3 randomised trial comparing Cisplating/Doxorubicin with Cisplatin alone for standard risk hepatoblastoma – A trial of the International Childhood Liver Tumour Strategy Group, SIOPEL.

Widing E, De Camargo B, Scopinaro M, Brock P, Brugieres L, Shafford E, Zsiros J, Morland B, Pritchard J, Childs M, Maibach R, Plaschkes J, Ablett S and Perilongo G.

SIOP Paediatric Blood & Cancer Vol43:Issue4:September 2004

Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL Group.

Walter Daniel Cacciavillano, Laurence Brugieres, Margaret Childs, Elizabeth Shafford, Penelope Brock, Jon Pritchard, Rudolf Maibach, Marcello Scopinaro, Giorgio Perilongo.

 

Eur Jr of Cancer 40 (2004) 2274-2279.

2003

Where do we stand with hepatoblastoma? A review.

Schnater JM, Kohler SE, Lamers WH, von Schweinitz D, Aronson DC. Pediatric Surgical Center of Amsterdam, Emma Children's Hospital AMC, Academic Medical Center, Amsterdam, The Netherlands.

Cancer. 2003 Aug 15;98(4):668-78

Multifocal hepatoblastoma: Is there a place for partial hepatectomy?

Patrizia Dall'Igno, Giovanni Cecchetto, Tiziana Toffolutti, Umberto Cillo, Attilio Cecchetto, Maurizio Guglielmi, Giorgio Perilongo, Jack Plaschkes.

 

Med Pediatr Oncol 2003;40:113-117

2002

Liver transplantation (LTx) for unresectable hepatoblastoma (HB). Experience from the first co-operative study of the International Society of Pediatric Oncology - SIOPEL I - Proposal of guidelines.

J.B. Otte1, P. Czauderna2, D.C. Aronson3, G. Perilongo4, J. Pritchard5, E. Shafford6, J. Brown7, J. Plaschkes8.

1St-Luc University Clinics, Brussels, Belgium ; 2Medical University of Gdansk, Poland ; 3Emma Children's Hospital AMC, Amsterdam, Netherlands) ; 4University of Padua, Italy ; 5King Faisal Hospital & Research Centre, Jeddah, Saudi Arabia ; 6St-Bartholomew's Hospital, London, UK ; 7University of Leeds, UK ; 8University of Bern, Switzerland.

Hepatocellular Carcinoma in Children: Results of the First Prospective Study of the International Society of Pediatric Oncology Group

P. Czauderna, G. Mackinlay, G. Perilongo, J. Brown, E. Shafford, D. Aronson, J. Pritchard, P. Chapchap, J. Keeling, J. Plaschkes, and J.B. Otte for the Liver Tumors Study Group of the International Society of Pediatric Oncology

J Clin Oncol 20:2798-2804.

Proceedings of the Bern Workshop on childhood hepatoblastoma pathology 
Zimmermann A, Plaschkes J, Perilongo G
Med Pediatr Oncol 2002 Nov; 39 ( 5 ), 473.

Hepatocellular carcinoma in children - treatment perspectives on the basis of international SIOPEL-1 trial experience. 
Czauderna P
Ann Diag Ped Pathol 2002, 6, 27-33

Adult vs. Childhood hepatocellular carcinoma - are they the same or different lesions? Biology, natural history, prognosis and treatment. 
Czauderna P
Med Pediatr Oncol 2002, 39, 519-523.

Cisplatin monotherapy and delayed surgery - an effective treatment for standard risk hepatoblastoma: final report of the SIOPEL2 study. (Abst.) 
Pritchard J., Perilongo G., Shafford E., Brugierese L., Brock P., Maibach R., Czauderna P., Aronson D.C., Childs M., Mackinlay G., Camargo B., Plaschkes J
Med Pediatr Oncol 2002, 39, 264, O-180.

High risk hepatoblastoma - final treatment results of the SIOPEL 2 study. (Abst.) 
Zsiros J., Brock P., Brugieres L., Perilongo G., Shafford E., Maibach R., Czauderna P., Aronson D.C., Childs M., Mackinlay G., Scopinaro M., Plaschkes J
Med Pediatr Oncol 2002, 39, 264, O-181.

Hepatoblastoma and low birth weight: a trend or chance observation? 
Feusner J, Plaschkes J
Med Pediatr Oncol. 2002 Nov;39(5):508-9.

Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.

Schnater JM, Aronson DC, Plaschkes J, Perilongo G, Brown J, Otte JB, Brugieres L, Czauderna P, MacKinlay G, Vos A. Pediatric Surgical Center Amsterdam (EKZ-AMC/VUmc), Amsterdam, The Netherlands.

Cancer 2002 Feb 15;94(4):1111-20

Cisplatin (CDDP) alone and delayed surgery; an effective treatment for standard risk (SR) hepatoblastoma (HB); the most relevant finding of the SIOPEL 2 study directed to childhood HB; three-years survival data.

Perilongo G, Shafford E, Brugieres L, Brock P, Maibach R, Czauderna P, MacKinlay G, Aronson D, Childs M, Rondelli R, Plaschkes J - For the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL).

ASCO abstract 2002

Metastatic hepatoblastoma treated with a dose intensive multiagent chemotherapy regimen; Results from the Second Study of the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology SIOPEL 2

Brock P, Shafford E, Brugieres L, Pritchard J, Perilongo P, Maibach R, Czauderna P, Aronson D, MacKinaly G, Childs M, Rondelli R, Plaschkes J.

 

ASCO abstract 2002

2001

Proceedings of an international research workshop on pediatric liver tumours, 18-20 March 1999, Berne, Switzerland. Into the year 2000. 
Plaschkes J, University Children's Hospital, Department of Pediatric Surgery, CH-3010 Berne, Switzerland. 
Med Pediatr Oncol 2001 Mar;36(3):380-2  

Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology (SIOP) - SIOPEL 1. (Abst.) 
Czauderna P., Mackinlay G., Perilongo G., Brown J., Shafford E., Vos A., Pritchard J., Keeling J., Plaschkes J., Otte J.B
Med Pediatr Oncol 2001, 37, 193, O-119.

Surgical aspects of the treatment of hepatoblastoma - experience of the first prospective study (SIOPEL-1). (Abst.) 
Aronson D., Schnater M., Plaschkes J., Perilongo G., Brown J., Staalman C., Czauderna P., Otte J.B., Mackinlay G., Vos A
Med Pediatr Oncol 2001, 37, 193, O-120.

SIOP Childhood Liver Tumour Study Group: SIOPEL - Annual overview report on hepatoblastoma (HB) clinical research. (Abst.)

 

Plaschkes J., Kellie S., Czauderna P., Maibach R., Shafford E., Staalman C., Childs M., Brugieres L., Mackinlay G., Perilongo G
Med Pediatr Oncol 2001, 37, 239, P-122.

2000

Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors.

Perilongo G; Brown J; Shafford E; Brock P; De Camargo B; Keeling JW; Vos A; Philips A; Pritchard J; Plaschkes J
Cancer 2000 Oct 15;89(8):1845-53   

Pretreatment prognostic factors for children with hepatoblastoma - results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1.

Brown J; Perilongo G; Shafford E; Keeling J; Pritchard J; Brock P; Dicks-Mireaux C; Phillips A; Vos A; Plaschkes JEur J Cancer 2000 Jul;36(11):1418-25

Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology.

Pritchard J; Brown J; Shafford E; Perilongo G; Brock P; Dicks-Mireaux C; Keeling J; Phillips A; Vos A; Plaschkes JJ Clin Oncol 2000 Nov 15;18(22):3819-28   

SIOPEL trials using preoperative chemotherapy in hepatoblastoma.

Perilongo G, Shafford E, Plaschkes JLancet Oncol 2000; 1: 94-100

Hepatoblastoma - microscopical residual disease after delayed surgery: prognostic implications. (Abst.) 
Brugieres L., Plaschkes J., Mackinlay G., Cecchetto G., Czauderna P., Aronson D
Med Ped Oncol 2000, 35, 177, O-33.

 

Hepatocellular carcinoma - therapeutic problem still to be solved - on the basis of international and polish experience within SIOPEL program. (Abst.) 
Czauderna P., Mackinlay G., Perilongo G., Otte J.B., Brown J., Shafford E., Vos A., Pritchard J., Keeling J., Plaschkes J
Med Sci Mon 2000, 6 Supl. 4, 30 (VII.5).

1999

Liver tumours.
Perilongo G; Shafford EA
Eur J Cancer 1999 Jun;35(6):953-8; discussion 958-9

Congenital hepatoblastoma: a distinct entity? 
Ammann RA; Plaschkes J; Leibundgut K
Med Pediatr Oncol 1999 Jun;32(6):466-8  

SIOPEL 3 - the third study of the SIOP Liver Tumour Study Group for Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). (Abst.) 
Shafford E., Perilongo G., Brock P., Brugieres L., Czauderna P., Mackinlay G., Maibach R., Mapp T., Mayo G., Staalman C., Zimmerman A., Plaschkes J
Med Pediatr Oncol 1999, 33, 177.

 

Hepatoblastoma - SIOPEL 2 Pilot Study. Preliminary Report. (Abst.) 
Perilongo G., Brugieres L., Shafford E., Staalman C., Czauderna P., Brock P., Mayo G., Mapp T., Rondelli R., Maibach R., Mackinlay G., Kellie S., Scopinaro M., Plaschkes J
Med Pediatr Oncol 1999, 33, 177.

1998

Hepatoblastoma: DNA nuclear content, proliferative indices, and pathology. 
Rugge M; Sonego F; Pollice L; Perilongo G; Guido M; Basso G; Ninfo V; Pennelli N; Gambini C; Guglielmi M; Fabiano A; Leandro G; Keeling JW
Liver 1998 Apr;18(2):128-33   

 

SIOPEL 2 PILOT STUDY ON HEPATOBLASTOMA (HB)---PRELIMINARY DATA.
Perilongo G, Brugieres L, Plaschkes J, Shafford L, Czauderna P, Ablett S.
Proceedings of ASCO, 1998, 17, 538a, *2065
UKCCSG Data Centre---University of Leicester, United Kingdom.

1996

 

Pre-operative chemotherapy-Cisplatin (PLA) and Doxorubicin (DO) PLADO for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC)-results after 2 years follow-up. 
Plaschkes J, Perilongo G, Shafford E, et al.
Med Ped Oncol 1996, 27: 256.

1995

 

Imaging of hepatic tumours
Imaging of embryonal abdominal tumours in children, Academical Thesis Amsterdam, 1995, ISBN 90-9008401-0, NUGI 742
Staalman CR
Department of Paediatric Radiology, Academic Medical Centre, Amsterdam, The Netherlands (copy available on request, mail to: staalman@worldonline.nl).

1994 

SIOP trial report - overall preliminary results of SIOPEL-1 for the treatment of hepatoblastoma (HB) with pre-operative chemotherapy - continuous infusion cisplatin and doxorubicin (PLADO)
Plaschkes J, Perilongo G, Shafford E, Brock P, Brown J, Dicks-Mireaux C, Habrand JL, Keeling J, Phillips A, Pritchard J, Vos A (1994)

SIOP trial report - acute toxicity of continuous infusion cisplatin and doxorubicin (PLADO) in the SIOPEL-1 study of hepatoblastoma (HB) and hepatocellular carcinoma (HCC).
Plaschkes J, Perilongo G, Shafford E, Brock P, Brown J, Dicks-Mireaux C, Habrand JL, Keeling J, Phillips A, Pritchard J, Vos A (1994)
Med Pediatr Oncol 23: 170

SIOP trial report - childhood hepatocellular carcinoma - preliminary results of the SIOPEL 1 study of pre-operative chemotherapy, continous infusion cisplatin and doxorubicin (PLADO).
Plaschkes J, Perilongo G, Shafford E, Brock P, Brown J, Dicks-Mireaux C, Habrand JL, Keeling J, Phillips A, Pritchard J, Vos A (1994)
Med Pediatr Oncol 23: 287

1993

Rationale and results of the International Society of Pediatric Oncology (SIOP) Italian pilot study on childhood hepatoma: surgical resection d'emblee or after primary chemotherapy?
Guglielmi M; Perilongo G; Cecchetto G; Rondelli R; Lanino E; Siracusa F
J Surg Oncol Suppl 1993;3:122-6